Drug Trial Radar · NCT05027802
A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.
Last checked: Nov 20, 2026Latest source record: Jun 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
61
Actual
Start
Mar 14, 2022
Primary completion
Nov 30, 2024
Study completion Nov 30, 2024
Sponsor
- Lead sponsor
- IpsenIndustry
- Sponsor type
- Industry
- First posted
- Aug 30, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 14 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective of this study is to further evaluate the safety and efficacy of palovarotene in adult and paediatric participants with FOP. The aim of the study is also to ensure treatment continuity to participants who have completed one of the parent studies (Study PVO-1A-301, Study PVO-1A-202 and Study PVO-1A-204) and who, in the investigator's judgement, may benefit from palovarotene therapy.
Conditions
- Fibrodysplasia Ossificans Progressiva (FOP)
Interventions
PalovaroteneDrug
Palovarotene will be taken orally once daily at approximately the same time each day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With All Treatment-emergent Adverse Events (TEAEs), Serious and Non-serious Treatment-emergent Adverse Events and Serious and Non-serious Treatment-related Treatment-emergent Adverse EventsTime frame: From signing the informed consent form (Day 1) up to 30 days post last dose, approximately 32 months
Locations
13 sites in 10 countries. Site status is shown where the registry gives one.
University of California San Francisco (UCSF)
San Francisco, California
Mayo Clinic
Rochester, Minnesota
Children's Hospital of Philidelphia
Philadelphia, Pennsylvania
The Perelman School of Medicine - The University of Pennsylvania
Philadelphia, Pennsylvania
Hospital Italiano de Buenos Aires
Buenos Aires, Argentina
Royal North Shore Hospital
Saint Leonards, New South Wales, Australia
Hospital Israelita Albert Einstein
Morumbi, São Paulo, Brazil
Toronto General Hospital
Toronto, Canada
Groupe Hospitalier Necker Enfants Malades
Paris, France
Istituto Giannina Gaslini
Genoa, Italy
Hospital Universitario Ramon y Cajal
Colmenar Viejo, Spain
Norrlands Universitetssjukhus
Umeå, Sweden
Royal National Orthopaedic Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.